Literature DB >> 22695745

Intra- and intertumor heterogeneities in total, chronic, and acute hypoxia in xenografted squamous cell carcinomas. Detection and quantification using (immuno-)fluorescence techniques.

C-A Maftei1, C Bayer, K Shi, P Vaupel.   

Abstract

BACKGROUND: Heterogeneously distributed hypoxia is a major characteristic of solid tumors. (Immuno-)fluorescence detection of hypoxia in experimental tumors is frequently assessed in a single central section; however, this may not necessarily be representative of the whole tumor. In order to determine whether analysis of one central section is exemplary of the whole tumor and whether different volumes have an impact on tumor oxygenation, we assessed the fractions of total (TH), chronic (CH), and acute hypoxia (AH) throughout different layers of tumors of varying volumes.
MATERIALS AND METHODS: Xenografted FaDu human squamous cell carcinomas of different volumes were investigated for intra- and intertumor heterogeneities. Tissue blocks located at the apical, central, and basal layer were sliced from individual tumors. Four serial cryosections were analyzed from each tissue block. Vital tumor tissue was explored for the distribution of Hoechst 33342 (perfusion), pimonidazole (hypoxia), and CD31 (endothelium) to assess TH, CH, and AH.
RESULTS: Fractions of TH, CH, and AH were consistently similar in the serial sections of individual tissue blocks. However, significant differences were found between the apical, central, and basal blocks that were even opposite depending on the tumor volume. Pooled data from all three tissue blocks revealed significantly higher fractions of hypoxia in the large tumors than in the small tumors.
CONCLUSION: FaDu tumors exhibit a heterogeneous and volume-dependent oxygenation status. Assessing the average fractions of TH, CH, and AH from central blocks corresponds best to the average of the entire tumor. However, information on intratumor heterogeneities is lost, especially when considering tumors of substantially different volumes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695745     DOI: 10.1007/s00066-012-0105-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  40 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: evaluation using pattern recognition in microcirculatory supply units.

Authors:  Constantin-Alin Maftei; Christine Bayer; Kuangyu Shi; Sabrina T Astner; Peter Vaupel
Journal:  Radiother Oncol       Date:  2011-10       Impact factor: 6.280

3.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.

Authors:  J M Brown
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

4.  Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers.

Authors:  Constantin-Alin Maftei; Kuangyu Shi; Christine Bayer; Sabrina T Astner; Peter Vaupel
Journal:  Radiother Oncol       Date:  2011-06-28       Impact factor: 6.280

5.  Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?

Authors:  Ala Yaromina; Tobias Hölscher; Wolfgang Eicheler; Andrea Rosner; Mechthild Krause; Franziska Hessel; Cordula Petersen; Howard D Thames; Michael Baumann; Daniel Zips
Journal:  Radiother Oncol       Date:  2005-08       Impact factor: 6.280

6.  Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET.

Authors:  Kelin Wang; Ellen Yorke; Sadek A Nehmeh; John L Humm; C Clifton Ling
Journal:  Med Phys       Date:  2009-10       Impact factor: 4.071

7.  Relationship between size and oxygenation status of malignant tumors.

Authors:  R Manz; J Otte; G Thews; P Vaupel
Journal:  Adv Exp Med Biol       Date:  1983       Impact factor: 2.622

Review 8.  Detection and characterization of tumor hypoxia using pO2 histography.

Authors:  Peter Vaupel; Michael Höckel; Arnulf Mayer
Journal:  Antioxid Redox Signal       Date:  2007-08       Impact factor: 8.401

9.  Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas.

Authors:  Anna S E Ljungkvist; Johan Bussink; Paulus F J W Rijken; Johannes H A M Kaanders; Albert J van der Kogel; Juliana Denekamp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

10.  Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?

Authors:  Morten Busk; Michael R Horsman; Steen Jakobsen; Kim V Hansen; Johan Bussink; Albert van der Kogel; Jens Overgaard
Journal:  Radiother Oncol       Date:  2009-09-02       Impact factor: 6.280

View more
  4 in total

1.  Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.

Authors:  B Henriques de Figueiredo; T Merlin; H de Clermont-Gallerande; M Hatt; D Vimont; P Fernandez; F Lamare
Journal:  Strahlenther Onkol       Date:  2013-11-01       Impact factor: 3.621

2.  In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine.

Authors:  M Langenbacher; R J Abdel-Jalil; W Voelter; M Weinmann; S M Huber
Journal:  Strahlenther Onkol       Date:  2013-01-31       Impact factor: 3.621

3.  Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.

Authors:  Kuangyu Shi; Christine Bayer; Sabrina T Astner; Florian C Gaertner; Peter Vaupel; Markus Schwaiger; Sung-Cheng Huang; Sibylle I Ziegler
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

Review 4.  Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.

Authors:  Franziska Eckert; Kerstin Zwirner; Simon Boeke; Daniela Thorwarth; Daniel Zips; Stephan M Huber
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.